Quote from VigiServe Admin on February 8, 2026, 1:58 AM

In Liechtenstein, Pharmacovigilance is unique because it operates without an independent national system. Instead, it is fully integrated into the Swiss regulatory framework via a customs union treaty. Swissmedic (Swiss Agency for Therapeutic Products) acts as the de facto authority, and all rules are identical to Swiss (and by extension, largely EU) regulations.

1. Clinical Safety (Clinical Trials)

Clinical trials are rare but strictly regulated under the Swiss Therapeutic Products Act (TPA) and coordinated through Swissmedic.

• Approvals: Trials require authorization from Swissmedic. Liechtenstein participates in the EU CTIS (Clinical Trials Information System) via cooperation agreements.

• Expedited Reporting: Sponsors must report Suspected Unexpected Serious Adverse Reactions (SUSARs) aligned with ICH E2A:

  • Fatal or Life-Threatening: Within 7 calendar days.

  • Other Serious Unexpected: Within 15 calendar days.

• Periodic Reporting: Development Safety Update Reports (DSURs) are mandatory annually (ICH E2F format).

• Submission: Reporting is routed through CTIS or directly to Swissmedic; there is no separate Liechtenstein reporting channel.

2. Post-Marketing Pharmacovigilance

Post-approval obligations are indistinguishable from those in Switzerland.

• Personnel:

  • QPPV: A Qualified Person for Pharmacovigilance is mandatory (EU GVP-aligned).

  • Local Contact: If the QPPV is not based in Switzerland/Liechtenstein (e.g., an EU QPPV is used), a Local Contact Person residing in Switzerland or Liechtenstein is required for liaison purposes.

• Documentation: A Pharmacovigilance System Master File (PSMF) is mandatory (EU GVP Module II). It must be maintained and available for Swissmedic inspections.

• Incident Reporting (ICSRs):

  • Serious Cases: Report within 15 calendar days.

  • Non-Serious Cases: Report within 90 calendar days.

  • Submission: Mandatory electronic reporting via E2B(R3) standards to Swissmedic.

• Risk & Periodic Reporting:

  • PSURs: Submitted in ICH E2C(R2) format. Typically every 6 months (first 2 years), then annually.

  • RMPs: Mandatory for new active substances and high-risk products (EU GVP Module V).

  • Additional Monitoring: The Black Triangle (▼) scheme applies to new or high-risk medicines.

Summary of Requirements

Component	Requirement in Liechtenstein
Regulatory Authority	Swissmedic (via FL-CH Treaty)
Framework	Swiss TPA / EU GVP Aligned
Local Personnel	QPPV (EU/CH based) + Local Contact (if QPPV is foreign)
PSMF	Required
SUSAR Reporting	7 days (fatal) / 15 days (other serious)
ICSR Timelines	15 days (serious) / 90 days (non-serious)
RMPs	Mandatory (EU Style)
Special Monitoring	Black Triangle (▼) Scheme applies